Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. The principal activities of the Company are the development, manufacture and marketing of a range of generic, branded and in-licensed pharmaceutical products. The firm operates through three segments: Injectables, Branded and Generics. The Injectables segment supplies hospitals across its markets with generic injectable products, supported by its manufacturing facilities in the United States, Europe and Middle East/North Africa (MENA). The company is also engaged in the finished dosage form (FDF) business and has a manufacturing facility in Cleveland, Ohio. The Branded segment supplies branded generics and in-licensed patented products from its local manufacturing facilities to retail and hospital customers across the MENA region. The Generics segment supplies oral and other non-injectable generic and specialty products to the United States retail market, leveraging its manufacturing facility in Columbus, Ohio.
Mr. Riad Mishlawi is the Chief Executive Officer of Hikma Pharmaceuticals PLC, joining the firm since 2011.
What is the price performance of Hikma Pharmaceuticals plc. stock?
The current price of Hikma Pharmaceuticals plc. is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Hikma Pharmaceuticals PLC?
Hikma Pharmaceuticals PLC belongs to Pharmaceuticals industry and the sector is Health Care
What is Hikma Pharmaceuticals PLC market cap?
Hikma Pharmaceuticals PLC's current market cap is $NaN
Is Hikma Pharmaceuticals PLC a buy, sell, or hold?
According to wall street analysts, 15 analysts have made analyst ratings for Hikma Pharmaceuticals PLC, including 6 strong buy, 10 buy, 4 hold, 0 sell, and 6 strong sell